Evolus, Inc. Common Stock (LSX:A2JDYX) People
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Gill Other companies: Telix Pharmaceuticals Limited (Chair & Independent Non-Executive Director · Since at least May 11, 2026); Y mAbs Therapeutics (Director · Since at least Sep 20, 2018); Strongbridge Biopharma plc (Director · Sep 3, 2019 – Oct 5, 2021 · Past); STRATA Skin Sciences, Inc. (Director · May 30, 2018 – Nov 22, 2019 · Past); Melinta Therapeutics Inc (Director · May 25, 2018 – Jun 11, 2019 · Past); Ocugen, Inc. (Director · Dec 9, 2016 – Jun 15, 2018 · Past); Cempra Inc (Director · Jan 1, 2016 – Jan 3, 2017 · Past); EndoChoice Holdings Inc (President and CFO · Aug 14, 2015 – Nov 22, 2016 · Past) | Director · Since at least Feb 12, 2018 |
| Peter C Farrell Other companies: Arcturus Therapeutics Holdings Inc. (Director · Since at least Jan 1, 2019); ResMed Inc. (Director · Since at least Apr 2, 2007); NuVasive Inc (Director · May 24, 2007 – May 3, 2018 · Past) | Director · Jul 15, 2019 – Jan 27, 2023 · Past |
| David Moatazedi Other companies: Biomerica, Inc. (President and Chief Executive Officer · Since at least Dec 7, 2022); Vyome Holdings, Inc. (Director · Mar 13, 2017 – Jul 23, 2019 · Past) | President and Chief Executive Officer · Since at least May 6, 2018 |
| Karah Parschauer Other companies: Tenaya Therapeutics, Inc. (Board Member · Since at least Oct 18, 2024); Ultragenyx Pharmaceutical Inc. (EVP and Chief Legal Officer · Since at least Mar 1, 2024) | Director · Since at least Jan 30, 2024 |
| Albert G White III Other companies: The Cooper Companies, Inc. (President & CEO, Director · Since at least Sep 5, 2025) | Director · Since at least Jun 9, 2025 |
| Crystal Muilenburg Other companies: PMGC Holdings Inc. (Director · Nov 13, 2023 – Nov 13, 2023 · Past) | Chief Marketing Officer · Feb 25, 2021 – Mar 8, 2022 · Past |
| Michael M Jafar Other companies: Desktop Metal Inc (CEO, DESKTOP HEALTH · Aug 11, 2021 – Jun 1, 2022 · Past) | See Remarks · Oct 28, 2020 – Jan 27, 2021 · Past |
| Sandra Beaver Other companies: Tandem Diabetes Care, Inc. (Director · Since at least Nov 7, 2025) | Chief Financial Officer · Sep 5, 2022 – May 13, 2025 · Past |
| Vikram Malik Other companies: AEON Biopharma, Inc. (President, Director · Feb 8, 2021 – Feb 8, 2021 · Past) | Director · Since at least Feb 7, 2018 |
| Brady Stewart | Director · Since at least Feb 7, 2024 |
| Donna Lynne Colonna | Director of Medical Affairs, RN, BSN, Certified Nurse Injector, Certified Plastic Surgery Nurse · Since at least Nov 5, 2026 |
| J Christopher Marmo | Chief Operating Officer · Feb 7, 2018 – Feb 7, 2018 · Past |
| Jeff Plumer | General Counsel · Since at least Nov 4, 2026 |
| Jessica Novak | Chief People Officer · Since at least Nov 4, 2026 |
| Jon Yerbury | Senior Vice President, Operations · Since at least Nov 4, 2026 |
| Kourtney Cavallio | Senior Vice President, Marketing · Since at least Nov 5, 2026 |
| Kristine Romine | Director · Feb 7, 2018 – Jan 23, 2020 · Past |
| Kurt Knab | Senior Vice President, Sales · Since at least Nov 4, 2026 |
| Meha Patel | Director of Medical Affairs, PA-C, MSPAS · Since at least Nov 5, 2026 |
| Monica Champaneria | Evolus Medical Affairs Operations & Event Manager · Since at least Nov 5, 2026 |
| Nareg Sagherian | Vice President, Head of Global Investor Relations and Corporate Communications · Since at least Oct 1, 2026 |
| Peter Kreymerman | Evolus VP & Head of Global Medical Affairs, Assistant Professor of Plastic Surgery at Campbell University · Since at least Nov 5, 2026 |
| Robert Hayman | Director · Feb 5, 2021 – Feb 7, 2024 · Past |
| Rui Avelar | Chief Medical Officer and Head of Research and Development · Since at least Aug 25, 2025 |
| Simone Blank | Director · May 20, 2019 – Mar 7, 2025 · Past |
| Tatjana Mitchell | Chief Financial Officer · Since at least Sep 8, 2025 |
| Tomoko Yamagishi-Dressler | Chief Marketing Officer · Since at least Feb 7, 2024 |
| Umberto La Magna | Senior Vice President, Evolus International · Since at least Nov 5, 2026 |